×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Videos
Maps
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Omeros Corporation to Announce First Quarter Financial Results on May 15, 2024
Business Wire
Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter and year ended March 31...
11 hours ago
Omeros Corporation to Announce First Quarter Financial Results on May 15, 2024
Chronicle-Tribune
SEATTLE--(BUSINESS WIRE)--May 10, 2024--. Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial...
11 hours ago
Omeros (OMER) Reports Q4 Loss, Misses Revenue Estimates
Yahoo News New Zealand
Omeros (OMER) delivered earnings and revenue surprises of 15.63% and -41.76%, respectively, for the quarter ended December 2020.
3 days ago
Brighton Jones LLC Sells 14000 Shares of Omeros Co. (NASDAQ:OMER)
Defense World
Read Brighton Jones LLC Sells 14000 Shares of Omeros Co. (NASDAQ:OMER) at Defense World.
5 days ago
Omeros Corporation Announces Upcoming Presentations at 2024 European Hematology Association (EHA) Hybrid ...
Business Wire
Omeros Corporation (Nasdaq: OMER) today announced that interim analysis data from its ongoing Phase 2 study of OMS906 in patients with...
1 day ago
Omeros terminates development of kidney disease therapy after study failure
Reuters
Omeros Corp said on Monday it will discontinue development of an experimental therapy to treat a type of kidney disease after a late-stage...
6 months ago
Omeros Corporation's (NASDAQ:OMER) 19% loss last week hit both individual investors who own 46% as well as institutions
Simply Wall Street
Key Insights Significant control over Omeros by retail investors implies that the general public has more power to...
3 weeks ago
Omeros stops kidney disease phase 3 after interim review fail, cutting thread holding up stock price
Fierce Biotech
Omeros stopped a phase 3 trial of narsoplimab in kidney disease patients after an interim analysis found it was destined to fail.
6 months ago
Omeros Shares Plummet on Phase III Kidney Disease Trial Failure
BioSpace
The biopharma discontinued its late-stage study after an interim review found that its investigational treatment for immunoglobin A...
6 months ago
Australian Police Charge Four Men in Gold Coast Crypto Money Laundering Case
Coinspeaker
Police charged the individuals with one count of money laundering each after investigations revealed that they were involved in a scam.
1 week ago